Media coverage about RXi Pharmaceuticals Corporation (NASDAQ:RXII) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. RXi Pharmaceuticals Corporation earned a coverage optimism score of 0.01 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.0121836892083 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news stories that may have effected Accern’s analysis:

RXi Pharmaceuticals Corporation (NASDAQ RXII) traded down 2.08% on Monday, reaching $0.47. 282,918 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $0.56 and its 200 day moving average price is $0.63. RXi Pharmaceuticals Corporation has a 52-week low of $0.32 and a 52-week high of $2.93. The firm’s market capitalization is $10.93 million.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). During the same quarter last year, the firm posted ($0.34) EPS. On average, analysts predict that RXi Pharmaceuticals Corporation will post ($1.77) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “RXi Pharmaceuticals Corporation (RXII) Given Daily News Impact Rating of 0.01” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at

In other RXi Pharmaceuticals Corporation news, insider Alexey Eliseev sold 176,800 shares of RXi Pharmaceuticals Corporation stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $0.54, for a total transaction of $95,472.00. Following the completion of the sale, the insider now owns 1,100,931 shares of the company’s stock, valued at approximately $594,502.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.71% of the stock is currently owned by company insiders.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Insider Buying and Selling by Quarter for RXi Pharmaceuticals Corporation (NASDAQ:RXII)

Receive News & Stock Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related stocks with our FREE daily email newsletter.